[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]

Andrea Belisari, Sergio Iannazzo, Giuseppe Di Pasquale, Claudio Fresco, Lorenzo Giovanni Mantovani, Maria Pia Ruggeri, Danilo Toni, Raffaele Landolfi

DOI: https://doi.org/10.7175/fe.v17i2.1243

Abstract

BACKGROUND: Each drug therapy with an anticoagulant effect may require, in emergency conditions, a rapid and specific strategy for a prompt restoration of coagulation. Dabigatran is the first-in-class of the so-called new oral anticoagulants (NAO), that have been made available in recent years in addition to traditionally-used vitamin K antagonists (VKA). Idarucizumab is a monoclonal antibody that binds to dabigatran, neutralizing its anticoagulant effect.
OBJECTIVE: To assess the economic effect of idarucizumab in patients treated with dabigatran when the rapid reversal of its anticoagulant effect is required.
METHODS: The analysis was carried over through the development of a budget impact model specifically adapted to the context of Italian care. The analysis was conducted along a time horizon of five years. The target population was defined by those patients on dabigatran treatment presenting uncontrolled and life-threatening bleedings (gastro-intestinal, intracranial or other) or requiring emergency surgery or urgent procedures. The estimation of healthcare resources (i.e. diagnostic procedures, medications, and other in-hospital services) needed for the management of uncontrolled bleeding and emergency surgery in patients treated with dabigatran was obtained from a panel of five Italian Clinical Experts. Unit costs were derived from current prices and tariffs.
RESULTS: The total cost of management with the current therapeutic modalities ranged from € 16.5 million in year 1 to € 20.1 million in year 5. In the scenario with idarucizumab the total cost ranged from € 15.4 million in year 1 to € 18.7 million in year 5. The adoption of idarucizumab resulted in a cumulative 5-year savings of 6.5 million euro corresponding to 7.1% of the total expense.
CONCLUSION: Idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations has the potential for substantial savings, compared to treatments currently available. This preliminary assessment will require further confirmatory evidence when the product will become available in Italian healthcare setting.

[Article in Italian]

Keywords

Dabigatran, Idarucizumab, Emergency surgery; Urgent procedures

Full Text

HTML PDF

References

  • Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47; http://dx.doi.org/10.1093/eurheartj/ehs253
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-51; http://dx.doi.org/10.1056/NEJMoa0905561
  • EMA/CHMP/623992/2015. EMA fast-tracks antidote to anticoagulant Pradaxa. Press release, 25 September 2015. Disponibile online su: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/09/WC500194183.pdf
  • Agenzia Italiana Del Farmaco. Determina 2 febbraio 2016. Classificazione, ai sensi dell’articolo 12, comma 5, legge 8 novembre 2012, n. 189, del medicinale per uso umano «Praxbind», approvato con procedura centralizzata. (Determina n. 173/2016). GU Serie Generale n.44 del 23-2-2016
  • Praxbind. Riassunto delle Caratteristiche di Prodotto
  • Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-20; http://dx.doi.org/10.1056/NEJMoa1502000
  • Sullivan SD, Mauskopf JA, Augustovski F, et al. Principles of good practice for budget impact analysis II: Report of the ISPOR task force on good research practices – budget impact analysis. Value Health 2014:17: 5-14; http://dx.doi.org/10.1016/j.jval.2013.08.2291
  • Ministero della Salute. Assistenza, ospedale e territorio. 118 e Pronto Soccorso. Pronto Soccorso e DEA. Disponibile online su: http://www.salute.gov.it
  • Ministero Della Salute. Decreto 18 ottobre 2012. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. GU Serie Generale n.23 del 28-1-2013 - Suppl. Ordinario n. 8
  • Conferenza Permanente Per I Rapporti Tra Lo Stato Le Regioni E Le Province Autonome Di Trento E Bolzano. Accordo 24 luglio 2003. Accordo tra il Ministro della salute, le regioni e le province autonome di Trento e di Bolzano sul documento recante: «Aggiornamento del prezzo unitario di cessione del sangue e degli emocomponenti tra servizi sanitari pubblici». GU Serie Generale n.228 del 1-10-2003
  • Agenzia Italiana Del Farmaco. Determinazione 5 agosto 2006. Rinegoziazione dei prezzi di cessione alle strutture pubbliche del Servizio sanitario nazionale dei medicinali emoderivati. GU Serie Generale n.182 del 7-8-2006
  • Agenzia Italiana Del Farmaco. Determinazione 29 settembre 2009. GU Serie Generale n.241 del 16-10-2009 - Suppl. Ordinario n. 189
  • Agenzia Italiana Del Farmaco. Comunicato. GU Serie Generale n.29 del 5-2-2010 - Suppl. Ordinario n. 23
  • Agenzia Italiana Del Farmaco. Determinazione 4 dicembre 2008. GU Serie Generale n.295 del 18-12-2008
  • Ministero della Salute. Progetto Mattoni SSN. Pronto Soccorso e sistema 118. Disponibile online su: http://www.mattoni.salute.gov.it/mattoni/documenti/11_Valutazione_costi_dell_emergenza.pdf
  • Centro Studi Sociali Pietro Desiderato. Costo giornaliero della degenza nelle regioni italiane. http://www.csspd.it/download/ALLEGATI_CONTENUTI/SS_120706_costo_degenze.pdf
  • GiViTI - Gruppo italiano per la Valutazione degli interventi in Terapia Intensiva. Progetto ToDo - Anno 2005. Rapporto generale. Disponibile online su: http://www.giviti.marionegri.it/Download%5CRapportoToDo.pdf
  • Ferreira J, DeLosSantos M. The clinical use of prothrombin complex concentrate. J Emerg Med 2013; 44: 1201-10; http://dx.doi.org/10.1016/j.jemermed.2012.12.022
  • Jones CA, Ducis K, Petrozzino J, et al. Prevention of treatment-related fluid overload reduces estimated effective cost of prothrombin complex concentrate in patients requiring rapid vitamin K antagonist reversal. Expert Rev Pharmacoecon Outcomes Res 2016; 16: 135-9; http://dx.doi.org/10.1586/14737167.2015.1071194
  • Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emergency medicine journal : EMJ. Feb 2014;31(2):163-168; http://dx.doi.org/10.1136/emermed-2012-201976
  • Miller MP, Trujillo TC, Nordenholz KE. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. Am J Emerg Med 2014; 32: 375-82; http://dx.doi.org/10.1016/j.ajem.2013.11.044
  • Majeed A, Hwang HG, Connolly SJ, et al. Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation 2013; 128: 2325-32; http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002332
  • Kooman J, Basci A, Pizzarelli F, et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007; 22 Suppl 2: ii22-44; http://dx.doi.org/10.1093/ndt/gfm019
  • Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-38; http://dx.doi.org/10.1160/TH11-01-0052
  • Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2: 217-25; http://dx.doi.org/10.1007/s12245-009-0125-8
  • Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800; http://dx.doi.org/10.1056/NEJMoa1006221
  • Douketis J, Healey J, Brueckmann M, et al. Bleeding and Thromboembolic Outcomes in Warfarin- and Dabigatran-treated Patients in the RE-LY ® Trial who Required an Urgent Surgery or Procedure. ISTH 2015 congress, Toronto, Canada, 20-25 June 2015

Statistics

Abstract: 2933 views
HTML: 1335 views
PDF: 520 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.